The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00001075
First received: November 2, 1999
Last updated: February 13, 2012
Last verified: February 2012

November 2, 1999
February 13, 2012
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00001075 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients
A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and Lamivudine (3TC) in Moderately Advanced HIV-1 Disease

To determine whether administration of a highly active antiretroviral treatment regimen consisting of ritonavir (ABT-538), zidovudine (AZT), and lamivudine (3TC) is associated with the restoration of delayed type hypersensitivity and lymphocyte proliferative responses in patients with moderately advanced HIV-1 infection. To better characterize in these patients the phenotype of the expanded lymphocyte subpopulations, as well as the genotype, phenotype, and cellular origin of viruses that persist after initiation of therapy, and the genotype and phenotype of drug-resistant isolates that emerge during therapy.

Although plasma viral load drops dramatically after initiation of powerful antiretrovirals, it does not drop to zero. It appears that a new steady state is reached, suggesting that a reservoir may exist of virus-producing cells, possibly cells of monocyte/macrophage lineage, that continue to produce a low level of virus despite antiretroviral treatment.

Although plasma viral load drops dramatically after initiation of powerful antiretrovirals, it does not drop to zero. It appears that a new steady state is reached, suggesting that a reservoir may exist of virus-producing cells, possibly cells of monocyte/macrophage lineage, that continue to produce a low level of virus despite antiretroviral treatment.

Patients undergo 5 weeks of antiretroviral washout before initiating therapy with ritonavir alone for 9 days, followed by combination therapy with ritonavir, zidovudine, and lamivudine from day 10 through week 48. [AS PER AMENDMENT 1/31/97: The availability of the current, open-label study treatment has been extended to allow patients who have completed 48 weeks of therapy to continue protocol therapy until the last enrolled patient completes 48 weeks of study treatment.]

Interventional
Not Provided
Primary Purpose: Treatment
HIV Infections
  • Drug: Ritonavir
  • Drug: Lamivudine
  • Drug: Zidovudine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
55
July 2007
Not Provided

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Recombinant erythropoietin and/or G-CSF for AZT-related bone marrow suppression.
  • Antibiotics other than metronidazole.
  • PCP prophylaxis.
  • Regularly prescribed medications such as antipyretics, analgesics, allergy medicine, and oral contraceptives.
  • Vitamins and herbal therapies.

Concurrent Treatment:

Allowed:

  • Acupuncture.
  • Visualization techniques.

Patients must have:

  • Documented HIV infection.
  • CD4 count 100-300 cells/mm3.
  • At least 3 consecutive months of prior AZT at a dosage of 500-600 mg bid, but with 5 weeks of antiretroviral washout prior to study entry.
  • Consent of parent or guardian if less than 18 years old.

Prior Medication:

Required:

  • Prior AZT at 500-600 mg bid at any time.
  • PCP prophylaxis during antiretroviral washout.

Allowed:

  • Prior ddI and/or ddC.
  • Prior recombinant erythropoietin and/or G-CSF for AZT-related bone marrow suppression.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Chronic pancreatitis.
  • Psychological conditions that would affect compliance.
  • Intolerance to 500-600 mg/day AZT.
  • Concurrent participation on another antiretroviral research treatment study (study treatment for opportunistic infection or complications of HIV is allowed).
  • Considered likely to be noncompliant on study.

Concurrent Medication:

Excluded:

  • Immunomodulators such as systemic corticosteroids, thalidomide, or cytokines.
  • Rifabutin.
  • Disulfiram (Antabuse) or other medications with similar effects, including metronidazole.
  • Other drugs contraindicated with ritonavir.

[AS PER AMENDMENT 8/27/96: Immunization must be avoided during the antiretroviral washout period.]

Patients with the following prior conditions are excluded:

  • Active opportunistic infection or febrile illness with temperature >= 38.5 C within 3 days prior to study entry.
  • History of acute pancreatitis within the past 2 years.

Prior Medication:

Excluded:

  • Prior 3TC or a protease inhibitor.
  • Experimental drugs except those for HIV-related conditions, within the past 30 days.

[AS PER AMENDMENT 8/27/96: Immunization must be avoided prior to the antiretroviral washout period.]

Active substance abuse.

Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00001075
ACTG 315, 10688
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Study Chair: Lederman M
Study Chair: Kessler H
National Institute of Allergy and Infectious Diseases (NIAID)
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP